EGFR and adenocarcinoma: Several analyses on patients with adenocarcinoma, aged ≤ 40 years found 30-56.3% harbored EGFR mutations, 16.1-50% had ALK rearrangements, and ROS1 in 7% (54, 55, 58–62).